08:49 AM EDT, 10/20/2025 (MT Newswires) -- Olema Pharmaceuticals ( OLMA ) shares were down 30% in recent Monday premarket activity, after the company reported new data over the weekend from its phase 1b/2 trial of palazestrant in combination with ribociclib in patients with breast cancer.

Solana ( HSDT ) stock was over 19% lower after the company said in a regulatory filing Friday that it launched an offering on behalf of certain stockholders of up to 37.8 million of its class A common shares, 36.1 million underlying pre-funded warrants, and 81.3 million common stock underlying warrants.

Artiva Biotherapeutics ( ARTV ) shares were 8% lower, following Friday's surge.

Astera Labs ( ALAB ) stock was down more than 2%, after Barclays downgraded the company to equalweight from overweight with a $155 price target.